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The aim of medical science is to delay death. 
Therefore, even doctors die. 
However, their thesis would be immortal, intact and unread. 
 






POPULAR SCIENCE SUMMARY OF THE THESIS 
What is known? 
Gastric cancer (equivalent to ‘stomach cancer’) is one of the top 5 most common cancers 
globally. One in 33 men and 1 in 78 women develop gastric cancer over a lifetime. The most 
common (>90%) histological subtype of gastric cancer is gastric adenocarcinoma. The word 
‘adenocarcinoma’ represents cancer developing from glands (a type of normal human tissue) 
or having glandular structures. There are many risk factors for developing gastric cancer, 
including certain lifestyle habits such as smoking and physical inactivity, dietary factors such 
as high consumption of salt and pickled food, and infection of a specific bacteria named 
Helicobacter pylori. However, not all cases of gastric cancer could be explained by these 
factors, and more investigation is needed to understand the causes of this cancer. When 
occurring, the early symptoms of gastric cancer are often atypical (e.g. fatigue, loss of 
appetite), making early diagnosis very difficult and thus most patients are diagnosed at an 
advanced stage. As a result, the survival of patients with gastric cancer is generally not good; 
most patients die within 5 years after diagnosis. Hence, it is also vital to discover factors that 
could help improve the survival of gastric cancer. 
Diabetes is a common and chronic disease that is characterized by high blood sugar (glucose) 
levels. Diabetes could cause diseases in various organs, e.g. cardiovascular disease, kidney 
disease, eye disease, and foot ulcers. Recent studies have shown that diabetes may also be 
associated with occurrence of different cancers. However, whether diabetes is associated with 
gastric cancer is not clear because the results from previous studies are not consistent. 
Metformin is an oral glucose-lowering medication used among most adults with newly 
diagnosed diabetes. Interestingly, metformin has been found to have beneficial ‘side effects’ 
which may prevent against cancer development. The questions are whether metformin 
protects against the development of gastric cancer or improves the survival of it. 
What has been done? 
This thesis includes four so-called ‘cohort studies’ (Study I, III-V) and one so-called 
‘systematic review and meta-analysis’ (Study II). In cohort studies, we identify a specific 
large group of people and obtain some information (e.g. diabetes status or use of metformin) 
from them at a specific time. Then we follow them up over a period, usually several years or 
decades, and wait to see if they develop a disease under study (e.g. gastric cancer) or have an 
event under study (e.g. death due to gastric cancer). Thanks to the high-quality Swedish 
health data registries, we did not have to follow every one of the cohorts in person for 
decades, but only needed to apply for necessary data from the registries. On the other hand, 
the systematic review with meta-analysis is a scientific way to summarize all relevant 
existing evidence and integrate the evidence with a mathematic transformation. 
What is added by this thesis? 
In general, the studies in this thesis aimed to answer the following four questions, and the 
short answers are provided below:  
a) Does diabetes/high blood glucose levels increase the risk of developing gastric 
cancer? (Study I and II)  
Answer: Diabetes may not increase the chance of getting gastric cancer, but long-
term high blood glucose levels may do so. 
b) If a diabetes patient is diagnosed with gastric cancer, does diabetes influence his/her 
survival in gastric cancer? (Study III) 
Answer: Patients who have diabetes may have shorter survival in gastric cancer. 
c) Does taking metformin prevent the development of gastric cancer? (Study IV) 
Answer: No, taking metformin may not help to prevent gastric cancer. 
d) Does taking metformin improve the survival in gastric cancer? (Study V) 
























































Diabetes may increase the risk and mortality of certain cancers, but its association with 
gastric adenocarcinoma is not clear. On the other hand, metformin, a first-line treatment for 
diabetes, may reduce cancer risks and improve cancer-related survival, but these associations 
have not been confirmed in gastric adenocarcinoma as well. The aim of this thesis is to 
evaluate if and how diabetes or its biomarkers and the use of metformin influence the risk and 
prognosis of gastric adenocarcinoma. 
Study I investigated if diabetes or prediabetes influenced the risk of gastric adenocarcinoma 
in a population-based Swedish cohort. Participants of the Northern Swedish Health and 
Disease Study were included and followed up from 1985 to 2017. Participants exposed to 
diabetes or prediabetes, as confirmed by self-reports or oral glucose tolerance tests, were 
compared with those of normoglycaemia for the incidence of gastric adenocarcinoma, 
identified from the Swedish Cancer Registry. Cox proportional hazard regression analyses 
with adjustment for sex, age, calendar year, body mass index, tobacco smoking, and 
education level showed no associations between prediabetes or diabetes and the risk of gastric 
adenocarcinoma (hazard ratio [HR] 1.07, 95% confidence interval [CI] 0.79-1.44 for 
prediabetes; HR 0.77, 95% CI 0.46-1.29 for diabetes). 
Study II was a systematic review and meta-analysis assessing associations between serum 
Haemoglobin A1c (HbA1c) or glucose and the risk of developing gastric cancer, based on 
studies identified from three databases: MEDLINE, Embase and Cochrane library. The 
random-effects model showed that elevated levels of serum HbA1c were associated with an 
increased risk of gastric cancer (pooled HR 1.36, 95% CI 1.06-1.74), but not so for elevated 
levels of serum glucose (pooled HR 1.11, 95% CI 0.98-1.26).  
Study III was a population-based cohort study evaluating whether diabetes worsened the 
prognosis in gastric adenocarcinoma, including all patients diagnosed with gastric 
adenocarcinoma between 1990 and 2014 in Sweden. Co-existing diabetes at diagnosis of 
gastric adenocarcinoma was analysed by the Cox proportional hazard regression with the risk 
of mortality due to gastric adenocarcinoma (disease-specific mortality) as well as all-cause 
mortality. The HRs were adjusted for sex, age, calendar year, and co-morbidity. Patients with 
diabetes at diagnosis had a moderately increased risk of disease-specific mortality compared 
with those without diabetes (HR 1.17, 95% CI 1.11-1.22). Besides, diabetes was also 
associated with an increased risk of all-cause mortality among patients who underwent 
gastrectomy for gastric adenocarcinoma (HR 1.23, 95% CI 1.10-1.38). 
Study IV was a population-based cohort study assessing whether metformin use decreased 
the risk of gastric adenocarcinoma. All data were retrieved from four national health data 
registries and participants were selected from users of certain commonly prescribed 
medications. Two sub-cohorts were established, a diabetes cohort and a matched cohort. Cox 
proportional hazard regressions with adjustment for sex, age, calendar year, comorbidity, 
Helicobacter pylori eradication treatment, use of non-steroidal anti-inflammatory drugs, and 
use of statins were used to compare users and non-users of metformin in relation to the risk of 
gastric non-cardia and cardia adenocarcinoma. The risk of gastric non-cardia adenocarcinoma 
was not decreased among metformin users compared with non-users in either sub-cohorts 
(HR 0.93, 95% CI 0.78-1.12 in the diabetes cohort; HR 1.30, 95% CI 1.18-1.42 in the 
matched cohort). Besides, metformin use did not decrease, but rather increased the risk of 
gastric cardia adenocarcinoma in either sub-cohorts (HR 1.49, 95% CI 1.09-2.02 in the 
diabetes cohort; HR 1.58, 95% CI 1.38-1.81 in the matched cohort).  
Study V was a population-based cohort study aiming to test if pre-diagnosis use of 
metformin improved the prognosis in gastric adenocarcinoma. The study included all diabetes 
patients who were diagnosed with gastric adenocarcinoma between 2005 and 2018. 
Associations between metformin use within two years before the diagnosis of gastric 
adenocarcinoma and the risk of disease-specific and all-cause mortality were analysed with 
Cox proportional hazard regressions, with adjustment for sex, age, calendar year, 
comorbidity, use of non-steroidal anti-inflammatory drugs, and use of statins. Metformin use 
was associated with a decreased risk of disease-specific mortality (HR 0.79, 95% CI 0.67-
0.93) and all-cause mortality (HR 0.78, 95% CI 0.68-0.90) among diabetes patients with 
gastric adenocarcinoma.  
To conclude, diabetes or prediabetes did not increase the risk of gastric adenocarcinoma in 
the Swedish population of Study I, but aggregated evidence indicated that long-term 
hyperglycaemia may increase the risk of gastric cancer (Study II). Gastric adenocarcinoma 
patients with co-existing diabetes had a higher risk of disease-specific mortality compared 
with those without diabetes (Study III). Besides, although metformin use might not prevent 
gastric adenocarcinoma (Study IV), it may improve the prognosis of this cancer among 
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Diabetes is a chronic disease with increasing prevalence. The traditional classification of 
diabetes is type 1 diabetes, type 2 diabetes, gestational diabetes, and other types of diabetes. 
Hyperglycaemia is the common hallmark for all diabetes, which could lead to disorders in 
multiple organs. Metformin is a commonly prescribed medication that decreases the serum 
levels of glucose and insulin, and is used as a first-line treatment for type 2 diabetes.  
Gastric cancer is one of the most common malignancies worldwide. Many risk factors have 
been identified for gastric cancer but its aetiology has not been fully understood. Major 
treatments for gastric cancer include gastrectomy, chemotherapy, or a combination of both. 
Despite these treatments, the prognosis of gastric cancer is generally poor, adding huge 
burdens to the patients, public health, and society.  
In clinical practice, gastric adenocarcinoma (the main histological type of gastric cancer) is 
often diagnosed in a patient with diabetes. Several studies have shown that diabetes may 
increase the risk of several cancers and also influence cancer-related survival. On the other 
hand, metformin has been found to have anti-cancer effects and is associated with decreased 
cancer risk and improved cancer prognosis. However, previous studies have provided 
inconsistent results on the associations between diabetes or metformin and gastric 
adenocarcinoma.  
The four population-based cohort studies and one systematic review and meta-analysis 
included in this thesis aimed to clarify associations between these two diseases. Specifically, 
Study I and II evaluated whether diabetes, prediabetes, or their biomarkers, i.e. serum 
Haemoglobin A1c (HbA1c) or glucose, are associated with an increased risk of developing 
gastric adenocarcinoma. Study III assessed the influence of co-existing diabetes on the 
disease-specific mortality among patients with gastric adenocarcinoma. Study IV addressed 
the question whether metformin use prevents the development of gastric adenocarcinoma. 
And Study V investigated the potential role of pre-diagnosis use of metformin in the 





2 LITERATURE REVIEW 
2.1 DIABETES 
2.1.1 Overview 
Diabetes is an ancient disease, the first record of which could be traced back to 1500. The 
first diagnostic criteria for diabetes were developed in 1979.1, 2 Over the past two centuries, it 
has been gradually recognized that diabetes represents a group of disorders affecting multiple 
organs of the human body. Diabetes is characterized by hyperglycaemia and is traditionally 
classified as type 1 diabetes, type 2 diabetes, gestational diabetes, and other types of diabetes. 
Prediabetes is a preclinical and asymptomatic stage of impaired glucose tolerance or impaired 
fasting glycaemia and is a high-risk state of developing diabetes.3 
 
2.1.2 Epidemiology and treatment 
Type 1 diabetes is a heritable disorder due to autoimmune destruction of pancreatic β cells, 
resulting in insulin deficiency and chronic hyperglycaemia.4 Most patients with type 1 
diabetes are diagnosed before adulthood and exogenous insulin replacement is immediately 
needed.5 Both the prevalence and incidence of type 1 diabetes are increasing globally, but 
with great variations among different countries.6-8 The discovery and application of insulin 
(and its analogues) are the milestones in the treatment of type 1 diabetes, and remain so 
although many other therapies have been explored.4, 9  
Type 2 diabetes is caused by pancreatic β-cell dysfunction and insulin resistance, leading to 
progressive hyperglycaemia. The population living with diabetes has been nearly quadrupled 
from 1980 to 2014, with around 90% of them having type 2 diabetes.10, 11 The increasing 
prevalence of type 2 diabetes is a combined effect of increased obesity, changes in lifestyle, 
and an aging population over the world.11 The treatment for type 2 diabetes includes lifestyle 
interventions, glycaemic control, and management of complications. At diagnosis, patients 
with type 2 diabetes usually remain around 20% of the pancreatic β-cell function. Thus, 
lifestyle interventions and oral glucose-lowering medications are usually the first-line 
treatments. However, with the continuous decline of β-cell function, most patients eventually 
need insulin to regulate their blood glucose.11, 12 A wide range of medications is available for 
type 2 diabetes treatment with a similar effect of lowering blood glucose, but their effect on 
circulating insulin is different. Exogenous insulin, insulin analogues, and sulfonylureas 
increase the circulating insulin levels; metformin and thiazolidinedione decrease circulating 
insulin levels; acarbose, glucagon-like peptide-1, and sodium-glucose linked transporter-2 
inhibitors have no clear effect on insulin levels; while dipeptidyl peptidase-4 has a complex 
effect of simultaneously decreasing insulin resistance and increasing insulin secretion.13, 14 
Compared with patients without diabetes, diabetes patients have an increased risk of overall 
mortality, and cardiovascular diseases are the main causes of death.15 
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2.2 DIABETES AND CANCER 
2.2.1 Diabetes and risk of cancer 
Many studies have shown that diabetes is associated with an increased overall cancer risk.16-19 
The influence of diabetes on cancer risk might be explained by two hypothesized 
mechanisms: 1) a direct pathway through the pathological changes following hyperglycaemia 
and hyperinsulinemia, and 2) an indirect pathway through shared risk factors for diabetes and 
cancer, e.g. aging, obesity, smoking, and dietary factors.20-22 Although the second hypothesis 
seems plausible, it is unlikely to explain all of the associations between diabetes and cancer 
risks, because these risk factors are also common in other diseases, e.g. hypertension, for 
which no increased cancer risks have been found. 
It has been proposed that the insulin/insulin-like growth factor (IGF) axis plays a key role in 
the carcinogenesis among diabetes patients. Insulin is a peptide hormone produced by 
pancreatic β-cells, and IGFs are polypeptides with structures resembling the structure of 
proinsulin.23, 24 Both insulin and IGFs are regulators of growth and energy metabolism. High 
concentrations of insulin activate IGF-I receptors and increase IGF-I bioavailability. The 
downstream of IGF-I receptors is the Akt and AMPK signalling networks that regulate the 
proliferation and apoptosis of cancer cells.23, 24 Besides, IGFs also interact with certain 
cancer-related molecules, including oestrogen, epidermal growth factor, interleukin-6, and 
tumour necrosis factor-α.20 
 
2.2.2 Diabetes and prognosis of cancer 
At cancer diagnosis, around 8% to 18% of patients have pre-existing diabetes, and among 
elderly cancer patients, the prevalence is even higher.25-27 A meta-analysis showed an 
increased risk of all-cause mortality (hazard ratio [HR] 1.41, 95% confidence interval [CI] 
1.28-1.55) among diabetic cancer patients compared with non-diabetic cancer patients.25 But 
all-cause mortality cannot be directly related to cancer-related survival in these patients, since 
diabetes is known to also increase the risk of death from many other causes.15 Studies 
evaluating the effect of diabetes on cancer-specific mortality are limited and the existing 
studies usually aggregated in certain cancer types whose risk is increased among diabetes 
patients.21, 28 Diabetes may influence the survival of cancer patients at different stages, 
including cancer screening, cancer detection, selection for curative surgery, postoperative 
short-term mortality, selection for adjuvant therapy, choice of dose and regimen for 





2.2.3 Metformin and cancer 
Metformin is the most widely evaluated anti-diabetes medication for its influence on cancer 
risk and survival. Most studies have examined cancers of the colorectum, prostate, and 
breast.30 The potential anti-cancer mechanisms of metformin include the direct activation of 
the AMPK pathway and indirect effects from lowering the circulating glucose and insulin 
levels.31 Besides, metformin may also increase the response rate to chemotherapies.28 When 
evaluating metformin studies, three specific methodological considerations should be taken 
into account. First, time-related bias, especially immortal time bias, are prominent in 
metformin studies and may exaggerate the protective effects of metformin.32 Second, 
confounding by indication may exist when the comparison is made among users of different 
anti-diabetes drugs. Third, dosages, cumulative duration of use, and exposure to other 
medications should be considered when interpreting the results.20, 33-36 
 
2.3 GASTRIC ADENOCARCINOMA 
2.3.1 The stomach 
The stomach is a j-shaped, muscular, hollow, and distensible organ located mainly on the left 
side of the upper abdominal cavity. It connects the distal oesophagus and the duodenum and 
is divided into four sections: cardia, fundus, body, and pylorus (Figure 1).37 The core function 
of the stomach is early-stage digestion during which the stomach works as a reservoir to store 
food, a factory to produce acids, hormones, and enzymes, as well as an engine to pulverize 
and transport food.38  
 
Figure 1. Sections of the stomach. Illustration by the author © 
 
2.3.2 Gastric cancer: Occurrence and classification 
Cancer of the stomach is also called gastric cancer and is an important component of the 
global cancer burden. In 2017, gastric cancer caused 19.1 million disability-adjusted life-
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years (DALYs), accounting for 8.2% of the total DALYs caused by all cancers.39 In 2020, 
gastric cancer was the 5th most common cancer and the 3rd  leading cause of cancer deaths.40 
Between 2006 and 2016, the overall incidence of gastric cancer increased by 15%, which was 
mainly attributed to a change in the population age structure and population growth.41 The 
incidence of gastric cancer differs markedly between geographical areas, with the highest 
rates in Eastern Asia and lowest in Northern America, Northern Europe, and most countries 
in Africa.42  
There are different approaches to classify gastric cancer into different subtypes. 
Anatomically, most (73%) gastric cancers are non-cardia cancer, whereas 27% are cardia 
cancers, i.e. locating close to the gastro-oesophageal junction.43 Gastric non-cardia and cardia 
cancers have different aetiology, geographical distribution, disease courses, and clinical 
treatment.44 During the past few decades, the incidence of gastric non-cardia cancer has 
decreased, while the incidence of gastric cardia cancer has been stable or increased.45 
Histologically, 95% of gastric cancers are adenocarcinomas, which means that the cancer 
originates from cells that line glands and make mucus. The development of gastric 
adenocarcinoma goes through a stepwise transition from normal mucosa through chronic 
atrophic gastritis and intestinal metaplasia, to dysplasia and carcinoma, also known as the 
Correa’s cascade.46 
 
2.3.3 Gastric cancer: Risk factors 
Many factors are involved in the development of gastric adenocarcinoma (Figure 2). Chronic 
atrophic gastritis, intestinal metaplasia, gastric ulcers, gastric polyps, previous gastric surgery 
(gastrectomy), and Ménétrier’s disease are preconditions that are associated with an increased 
risk of developing gastric adenocarcinoma.47 Aging, male sex, tobacco smoking, and family 
history are common risk factors for both gastric cardia and non-cardia adenocarcinoma.48 
Helicobacter pylori (H. pylori) infection is the most important risk factor for gastric non-
cardia adenocarcinoma.49 H. pylori infection triggers the Correa’s cascade and promotes 
gastric atrophy and intestinal metaplasia. Other risk factors for non-cardia gastric 
adenocarcinoma include a sedentary lifestyle, low socioeconomic status, high intake of salt 
and pickled food, as well as low consumption of fresh fruits and vegetables.48 Different from 
gastric non-cardia adenocarcinoma, gastric cardia adenocarcinoma is closely associated with 




Figure 2. Some important risk factors (male sex, obesity, tobacco smoking, salt consumption, pickled food, 
and H. pylori infection) for gastric cancer. Illustration by the author ©  
 
2.3.4 Gastric cancer: Treatment and prognosis 
Early-stage gastric adenocarcinomas are usually asymptomatic and most patients with gastric 
adenocarcinoma are therefore diagnosed at an advanced stage. The most common symptoms 
are anorexia, dyspepsia, weight loss, vomiting, and abdominal pain.50 In most cases, gastric 
adenocarcinoma is diagnosed by histological examination of biopsies at gastroscopy.51 
Treating gastric adenocarcinoma incorporates a multidisciplinary approach involving 
gastroenterologists, surgeons, oncologists, pathologists, radiologists, and dietitians.52 At 
present, radical surgical resection is the mainstay of curative treatment for gastric 
adenocarcinomas, while for selected early-stage cases, endoscopic resection is also curative.53 
For patients with resectable gastric adenocarcinoma of stage IB-III, preoperative 
chemotherapy followed by gastrectomy and D2 nodal dissection is recommended, and the 
laparoscopic approach is gaining popularity over open surgery.53 Adjuvant chemotherapy and 
chemo-radiotherapy may also improve overall survival in addition to gastrectomy in some 
cases. For patients with unresectable or metastatic gastric adenocarcinoma, systemic 
chemotherapy can improve survival and quality of life.53 The prognosis of gastric 
adenocarcinoma is poor in most countries. The global 5-year survival for gastric 
adenocarcinoma is generally between 20%-30%, with the exception of some high-risk areas 
(Japan and Korea) where endoscopic screening is performed routinely and gastric 
adenocarcinoma is often diagnosed at an early stage.54 In Sweden, the 5-year survival is 
around 18% for both gastric non-cardia and cardia adenocarcinoma.55  
 
2.4 DIABETES AND RISK OF GASTRIC ADENOCARCINOMA 
Previous studies investigating associations between diabetes and gastric adenocarcinoma 
have provided inconsistent results. Some studies found that diabetes increased the risk of 
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gastric adenocarcinoma, while no association was indicated in other studies.56-59 There are 
several explanations for the inconsistency, e.g. the heterogeneity of study populations, the 
methods of measurement of diabetes, the length of follow-up, and the adjustment for 
confounders. In a systematic review and meta-analysis pooling results from 12 studies, a 
stronger association between diabetes and risk of gastric adenocarcinoma was found in East 
Asian populations compared with Western populations.60 An influence of sex on the relation 
between diabetes and risk of gastric adenocarcinoma was also reported in several studies, but 
again with inconsistent results.61-64 Besides, the excess risk of gastric adenocarcinoma due to 
diabetes may not be constant over time. While the increased risk of gastric adenocarcinoma 
among diabetes patients during the early follow-up may be explained by detection bias,63 a 
study from Taiwan showed that diabetes increased the risk of gastric adenocarcinoma only 
after 5 years of follow-up,58 suggesting an association between diabetes duration and risk of 
gastric adenocarcinoma.  
Few studies have evaluated the associations between diabetes and risk of gastric non-cardia 
and cardia adenocarcinomas separately. One study from the United States reported that self-
reported diabetes was associated with an increased risk of gastric cardia adenocarcinoma, 
while a study from Korea found no increased risk of either gastric cardia or non-cardia 
adenocarcinoma related to diabetes.65, 66 Studies from Western countries have reported an 
increased risk of gastric adenocarcinoma specifically among type 1 diabetes patients, and a 
meta-analysis has summarized the increased relative risk of 41%.56, 67-71 Yet, the number of 
relevant studies of type 1 diabetes is limited and more observational studies are warranted to 
establish an association in other populations. 
The mechanisms of which diabetes may influence gastric carcinogenesis are generally similar 
to the above-mentioned ones for other cancers. Pre-clinical studies have provided evidence 
that insulin and exogenous IGFs promoted the proliferation of gastric cancer cells, and 
overexpression of IGFs has been found in specimens of gastric adenocarcinoma.72, 73 In 
addition, inhibition of the IGF signalling pathway reduced the proliferation and invasion of 
gastric cancer cells.74  
Diabetes may also act as a co-factor of H. pylori infection in the development of gastric 
adenocarcinoma. A higher prevalence of H. pylori infection among diabetic patients 
compared with non-diabetic controls has been reported in some studies,75-77 but not others.78, 
79 When compared with non-diabetic controls, diabetes patients were reported to have lower 
eradication rates and higher re-infection rates of H. pylori.80, 81 A Japanese study reported that 
coexistence of hyperglycaemia and H. pylori infection increased the risk of gastric 
adenocarcinoma compared with H. pylori infection alone, suggesting that hyperglycaemia 
may modify the carcinogenic effect of  H. pylori.82 No difference in risk of gastric 
adenocarcinoma between diabetic and non-diabetic patients after H. pylori eradication was 
reported in another Japanese study.83 The interaction between diabetes and H. pylori infection 
may potentially explain why the associations between diabetes and the increased risk of 
gastric adenocarcinoma were more often reported in Asian populations, where the prevalence 
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of H. pylori infection is higher than elsewhere. However, the interaction between diabetes 
and H. pylori infection in relation to the risk of gastric adenocarcinoma has only been 
analysed in Japanese populations, and whether this also exists in other populations is not 
clear. 
 
2.5 DIABETES AND PROGNOSIS OF GASTRIC ADENOCARCINOMA 
Few studies have examined the association between diabetes and the prognosis in gastric 
adenocarcinoma, and most of the available studies were not designed especially for gastric 
adenocarcinoma. Among studies that have evaluated diabetes and the risk of long-term 
mortality following the gastric cancer diagnosis, a Swedish study reported an increased risk 
of gastric-cancer-specific mortality (HR 1.18, 95% CI 1.08-1.29)84 and a Korean study 
showed an increased risk of all-cause mortaliy (HR 1.52, 95% CI 1.25-1.84) among diabetes 
patients compared with non-diabetic patients.85 The associations between diabetes and 
postoperative mortality (mostly short-term) after gastrectomy were investigated in some 
studies. Increased risk of postoperative mortality among patients with diabetes compared with 
those without was found in one study, but not others.86-88  
The mechanisms through which diabetes might increase the risk of mortality in gastric 
adenocarcinoma are less understood. Limited evidence has shown that diabetes seems not to 
influence the selection for gastrectomy, but increase the risk of postoperative 
complications.88, 89 In addition, high glucose levels may increase chemo-resistance among 
patients with gastric adenocarcinoma.90 It is still unclear whether pre-existing diabetes 
influences the detection of gastric adenocarcinoma, application of adjuvant therapy or dose 
and regimen used for, and the risk of tumour recurrence after gastrectomy. 
 
2.6 METFORMIN AND GASTRIC ADENOCARCINOMA 
Studies examining the use of metformin in relation to the risk of gastric adenocarcinoma are 
limited and their results are not consistent.91-93 Some studies, mostly from Asian populations, 
indicated that metformin use decreased the risk of gastric adenocarcinoma.91, 92, 94 In contrast, 
studies from Western populations usually did not find any association between metformin use 
and the risk of gastric adenocarcinoma, which is consistent with the results of a recent meta-
analysis.91, 95, 96 Besides, a reduction in risk of gastric adenocarcinoma was related to the 
duration of metformin use in a Korean study, suggesting a protective effect among long-term 
users of metformin.92 Very few studies have evaluated the role of metformin use in the 
prognosis of gastric adenocarcinoma. In a systematic review and meta-analysis, no 
associations were found between metformin use and survival of gastric adenocarcinoma 




3 RESEARCH AIMS 
The overarching aim of this thesis was to assess diabetes mellitus, as well as its treatment 
metformin, in relation to the risk and prognosis of gastric adenocarcinoma. 
The specific aims of the included studies were: 
• To evaluate the associations between diabetes or prediabetes and the risk of 
developing gastric adenocarcinoma  
• To summarize the existing evidence assessing the associations between serum levels 
of HbA1c and glucose and the risk of gastric cancer  
• To investigate the influence of pre-existing diabetes on the prognosis in gastric 
adenocarcinoma 
• To assess the association between metformin use and the risk of developing gastric 
adenocarcinoma 
• To explore the influence of metformin use on the prognosis in gastric adenocarcinoma 




4 MATERIALS AND METHODS 
4.1 OVERVIEW 
Table 1. Methods overview of the included studies 
 Study I Study II Study III Study IV Study V 
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‡ NSAID: Non-steroidal anti-inflammatory drug 
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4.2 DATA SOURCES 
Study I and III-V were fully or partly based on data retrieved from different Swedish national 
health data registries, while study I was also based on data from the Northern Sweden Health 
and Disease Study (NSHDS). The data of study II (a systematic review and meta-analysis) 
were identified from Embase, Medline, and Cochrane Library. 
 
4.2.1 Swedish Registries 
In Sweden, reporting health data to registries is mandatory according to the legislation (1990: 
1144 and 1998:543), contributing to the high completeness and quality of these registries. 
Every Swedish resident is assigned a unique personal identity number upon birth or 
immigration and this number was used to link individual data between registries. The detailed 
codes to identify variables in each registry are listed in the supplements. 
4.2.1.1 The Cancer Registry 
The Swedish Cancer Registry was founded in 1958 and records data related to cancer 
diagnosis for the whole Swedish population. The data retrieved from the Cancer Registry in 
this thesis include tumour site, histological type, tumour stage (since 2004), and date of 
diagnosis. Different versions of the International Classification of Diseases (ICD) have been 
used for coding cancer diagnosis in the Cancer Registry over time but ICD-7 and 
WHO/HS/CANC/24.1 are used throughout the periods. Data on tumour stage were available 
in the registry from 2004 and were reported based either on clinical or pathological 
evaluations. The register is updated once a year. The completeness of the diagnosis of gastric 
adenocarcinoma in the Cancer Registry is up to 98% and the positive predictive value is 
96%.97  
4.2.1.2 The Patient Registry 
The Swedish Patient Registry collects data on inpatient care throughout Sweden since 1987 
and covers specialized outpatient care since 2001. However, data on primary care in Sweden 
are not included in the Patient Registry. The following information was retrieved from the 
Patient Registry and utilized in this thesis: disease diagnosis, operation codes, and date of 
operation. The Swedish version of ICD is used for reporting in the Patient Registry with the 
Swedish version of ICD-9 from 1987 to 1997, and the Swedish version of ICD-10 afterward. 
The register is updated monthly. The diagnosis of diabetes in the Patient Registry is around 
88% complete when compared with the diabetes quality registry.98 For other diseases, the 
quality of the diagnosis data from the inpatient care is generally good, with the positive 
predictive values varying between 85 and 95%.99  
4.2.1.3 The Cause of Death Registry 
The Swedish Cause of Death Registry records data on date and causes of death from death 
certificates for all Swedish residents since 1952. Different versions of ICD (6-10) have been 
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used for reporting causes of death over time. The Cause of Death Registry is updated once a 
year for cause of death and continuously for date of death, with high completeness for the 
number of deaths (>99%) and underlying causes of death (96%).100 
4.2.1.4 The Prescribed Drug Registry 
The Swedish Prescribed Drug Registry is among the youngest registries in Sweden, 
implemented in July 2005. Data on all prescribed and dispensed drugs from pharmacies are 
recorded in this registry, accounting for 84% of the total drug sales in Sweden. The remaining 
16% are drugs sold over-the-counter or used in hospitals or nursing homes.101 Around 65%-
67% of the Swedish population have at least one record in the Prescribed Drug Registry 
every year.102, 103 The register is updated monthly. All dispensed drugs in the Prescribed Drug 
Registry are coded with the Anatomical Therapeutic Chemical (ATC) Classification and 
defined daily dose (DDD) is used for counting the amount of drug consumption. The data 
quality in the Prescribed Drug Registry is generally good since the data are collected 
electronically and checked by the Swedish eHealth Agency before recorded. 
 
4.2.2 Northern Sweden Health and Disease Study (NSHDS) 
The NSHDS is a biobank with survey data from three sources: The Västerbotten Intervention 
Program (VIP) cohort, the Northern Sweden Monitoring Trends and Determinants in 
Cardiovascular Disease (MONICA) cohort, and the Mammography Screening Project cohort. 
Study I was based on the VIP and MONICA cohorts. The VIP is an ongoing intervention 
program aiming at reducing morbidity and mortality from cardiovascular disease and 
diabetes. Each year, all residents living in the county of Västerbotten who turn 40, 50, or 60 
years of age are invited to participate the program, which involves a comprehensive survey 
and screening for risk factors for cardiovascular disease and diabetes, followed by individual 
counselling.104 The MONICA is a World Health Organization (WHO) program evaluating 
risk factors for cardiovascular disease in relation to mortality trends. Residents from counties 
of the Norrbotten and Västerbotten are randomly selected and stratified for sex and age 
groups to attend the program. The participants are asked to complete questionnaires, and 
physical examinations are performed by trained survey teams.105 The MONICA surveys have 
been conducted recurrently for six times and the latest one was in 2009.  
The VIP and MONICA programs are similar regarding the geographic settings, overlapping 
participants, recruitment periods (VIP from 1985 and MONICA from 1986), evaluation of 
lifestyle and dietary habits, and oral glucose tolerance tests (OGTT). These similarities 




4.3 STUDY DESIGN 
4.3.1 Study I 
4.3.1.1 Design 
Study I was a cohort study based on the NSHDS (VIP and MONICA) between 1985 and 
2017 investigating whether prediabetes or diabetes increased the risk of gastric 
adenocarcinoma. The exposures were classified as prediabetes, diabetes or both. Prediabetes 
and diabetes were defined by OGTT results according to the WHO standards. Participants 
with self-reported diabetes in the questionnaire were also included in the diabetes group. The 
outcome was gastric adenocarcinoma occurring during the follow-up. The eligible 
participants from VIP and MONICA were included in the study from the date of their first 
physical assessment and followed up until the diagnosis of gastric adenocarcinoma, death, or 
end of the study period (27th April 2017), whichever occurred first. During the follow-up, the 
exposure status was allowed to change as follows: from normal blood glucose 
(‘normoglycaemia’) to prediabetes, from normoglycaemia to diabetes, from prediabetes to 
diabetes, and from prediabetes to normoglycaemia.  
4.3.1.2 Statistical analysis  
Cox proportional hazard regression was used to analyse the associations between diabetes or 
prediabetes and the risk of gastric adenocarcinoma, providing HRs with 95% CIs. Attained 
age was the time scale and thus adjusted for in all analyses. Twelve covariates were 
considered as potential confounders: age, sex, calendar year of inclusion, body mass index 
(BMI), tobacco smoking, alcohol consumption, education level, marital status, physical 
activity level, intake of fruit and vegetables, daily salt intake, and daily energy intake. After a 
stepwise backward selection, only covariates that changed the estimates for at least 10% were 
kept in the model. The covariates remained in the final model were sex, calendar year of 
inclusion (1986–1994, 1995–2003, or 2004–2017), BMI (in tertiles), tobacco smoking (never 
smoker, ex-smoker, or current smoker), and education level (compulsory school or less, 
upper secondary school, or college or postgraduate level).  
The analyses were conducted separately comparing prediabetes status, diabetes status, or any 
of the former two with normoglycaemic status in relation to the risk of developing gastric 
adenocarcinoma. Besides, linear associations between the continuous fasting glucose or 2-h 
post-load glucose levels and the risk of gastric adenocarcinoma were tested. The Schoenfeld 
residuals were used to test the proportionality assumption and the assumptions were met for 
all analyses.  
4.3.2 Study II 
4.3.2.1 Design 
Study II was a systematic review and meta-analysis evaluating the existing evidence on the 
associations between serum levels of HbA1c or glucose and the risk of gastric cancer. Three 
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databases were searched with predefined search strategies: MEDLINE, Embase, and 
Cochrane Library. The first search was conducted in December 2019, and an update was 
carried out in January 2021. Reference lists of relevant articles were also searched manually. 
Two authors independently reviewed and screened for studies available in the English 
language, where HbA1c or glucose was measured before the occurrence of gastric cancer and 
estimates for the risk of gastric cancer were reported. When studies were based on overlapped 
study populations, only the one with the largest sample size was included. However, studies 
based on the same population that separately analysed HbA1c and glucose were regarded as 
two individual studies and were both included. All included studies went through 
independent quality assessment by two authors using a modified Newcastle-Ottawa Scale for 
cohort studies. If any disagreement occurred during the process, a third author was consulted.  
4.3.2.2 Statistical analyses 
The meta-analysis was conducted with a random-effects model using the generic inverse-
variance method and pooled HR was the risk estimate. For studies reporting serum HbA1c, 
the cut-off value was set at 6%. For studies reporting serum glucose, the cut-off values varied 
a lot in individual studies and the highest level was compared with the lowest. When 
appropriate, in studies using quartile or quintile cut-off values, the estimates were converted 
to a value that was equivalent to the tertiles to reduce heterogenity.106  
Cochran’s Q test and I2 statistics were used to assess the heterogeneity of the included 
studies. For Cochran’s Q test, a P value <0.1 was considered significant, and for I2 statistics, 
≤25% was considered low heterogeneity, 25%-49% moderate heterogeneity, and ≥50% high 
heterogeneity. Subgroup analyses by different study characteristics, i.e. sex, geographic area 
(Asian or non-Asian), risk of bias, adjustment for BMI (obesity), and adjustment for H. pylori 
infection, were used to identify potential sources of heterogeneity. Regarding publication 
bias, visual inspection of funnel plots was first used, followed by Egger’s test if asymmetry 
was identified, and a nonparametric trim-and-fill analysis if Egger’s test showed significant 
results. 
4.3.3 Study III 
4.3.3.1 Design 
Study III was a population-based cohort study in Sweden, aiming at investigating whether 
diabetes increased the risk of mortality in gastric adenocarcinoma. The total cohort included 
all diagnosed gastric adenocarcinoma patients in Sweden between 1990 and 2014. Based on 
the total cohort, two sub-cohorts were constructed, one including only patients with gastric 
non-cardia adenocarcinoma (the non-cardia sub-cohort), and the other one including only 
patients who underwent gastrectomy for gastric adenocarcinoma (the surgical sub-cohort). 
The exposure was coexisting diabetes diagnosed before or at the diagnosis of gastric 
adenocarcinoma. The primary outcome was mortality due to gastric adenocarcinoma 
(disease-specific mortality), but in the surgical sub-cohort, the outcome was all-cause 
mortality after gastrectomy. The participants were followed up from the diagnosis date of 
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gastric adenocarcinoma until death or end of the study (31st December 2014). All data were 
retrieved from the following three registries: the Swedish Cancer Registry, Patient Registry, 
and Cause of Death Registry.  
4.3.3.2 Statistical analyses 
Cox proportional hazard regression was used to analyse differences in risk of mortality 
comparing patients with and without diabetes, providing HRs with 95% CIs. In the analyses 
of the total cohort and the non-cardia sub-cohort, a multivariable model adjusted for sex, age 
at diagnosis, and calendar year of diagnosis was applied. In the analyses of the surgical sub-
cohort, the multivariable model was further adjusted for comorbidities, represented by the 
Charlson Comorbidity Index (CCI), a well-validated numeric tool to summarize the number 
and severity of certain groups of comorbidities.107 The CCI was scored as 0, 1, or ≥2 
throughout this thesis. The total cohort and the non-cardia sub-cohort were analysed 
separately for the entire follow-up, while the surgical sub-cohort was analysed with 
stratification of the postoperation periods (30 days, 90 days, 6 months, and 12 months). 
Besides, the total cohort was further stratified by CCI scores, gastrectomy, and tumour stage 
(I-II or III-IV). The proportionality assumption was tested by checking the log-log plots and 
was met in all analyses except for the stratified analysis by tumour stage. Therefore, the risk 
of mortality within 6 months and afterwards was analysed separately in the stratified analysis 
by tumour stage to allow for proportionality. 
 
4.3.4 Study IV 
4.3.4.1 Design 
Study IV was a Swedish population-based cohort study based on data from four Swedish 
national health data registries: the Swedish Prescribed Drug Registry, Cancer Registry, 
Patient Registry, and Cause of Death Registry. The question of interest was whether use of 
metformin decreased the risk of developing gastric adenocarcinoma. The study participants 
were sampled from adult individuals (>18 years) with dispensed records of certain commonly 
prescribed medications between 2005 and 2015, including the medications against diabetes. 
Participants with a history of any cancer diagnosis or gastrectomy were excluded.  
Two cohorts were constructed: a diabetes cohort and a matched cohort of common-
medication users (short for ‘matched cohort’). The exposure was the same in both cohorts, 
i.e. use of metformin. In the diabetes cohort, all cohort members were users of anti-diabetes 
medications and were included in the cohort at their first recorded dispensation of any anti-
diabetes medication. In the matched cohort, each metformin user was included on the first 
dispensation date of metformin, and 10 metformin non-users were randomly sampled on the 
same day from the rest of common-medication users and matched with the metformin user by 
sex and age (± 1 year). The exposure status was allowed to change in both cohorts. The 
primary outcome was gastric adenocarcinoma and gastric non-cardia and cardia 
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adenocarcinomas were also analysed separately. The two cohorts were followed up until the 
occurrence of gastric adenocarcinoma, death, or the end of the study (December 31st, 2015). 
4.3.4.2 Statistical analyses 
Cox proportional hazard regressions were used to calculate HRs with 95% CIs, comparing 
the risks of developing gastric adenocarcinoma as well as gastric cardia and non-cardia 
adenocarcinoma among users and non-users of metformin in two cohorts. A multivariable 
model was applied with adjustment for seven covariates: sex, age, calendar year at inclusion 
(2005, 2006–2010 or 2011–2015), CCI, H. pylori eradication treatment, use of non-steroidal 
anti-inflammatory drugs (NSAIDs), and use of statins. Because no information on H. pylori 
infection was available in the four registries, H. pylori eradication treatment was used as a 
surrogate covariate for H. pylori infection.108 The H. pylori eradication treatment was treated 
as a time-varying variable. Use of NSAIDs and use of statins were categorized as users or 
non-users and at least two dispensed records within the first year after the cohort entry were 
required for a participant to be identified as users of these medications. 
 
4.3.5 Study V 
4.3.5.1 Design 
Study V was a Swedish population-based cohort study based on the same four Swedish 
registries as Study IV. The study period was from 2005 through the end of 2019. Participants 
who had diabetes at the time of the diagnosis of gastric adenocarcinoma between 2005 and 
2018 were included in the study. The diagnosis of diabetes was based on at least one 
dispensed record of any anti-diabetes medication before the diagnosis of gastric 
adenocarcinoma. Patients with a history of any malignancy (except for non-melanoma skin 
cancer), or gestational diabetes, or polycystic ovarian syndrome were excluded. The exposure 
was metformin use within two years before gastric adenocarcinoma diagnosis. The primary 
outcome was death with gastric adenocarcinoma as one of the underlying causes (disease-
specific mortality) and the secondary outcome was all-cause mortality. The patients were 
followed up from their diagnosis date of gastric adenocarcinoma until death or end of the 
study period, whichever came first. 
4.3.5.2 Statistical analysis 
Cox proportional hazard regression was used to analyse mortality outcomes between 
metformin users and non-users, providing HRs with 95% CIs. A multivariable model with 
adjustment for six potential confounders was applied. These potential confounders were sex, 
age at gastric cancer diagnosis, calendar year at gastric cancer diagnosis (2005-2009, 2010-
2014, or 2015-2018), CCI scores, use of NSAIDs, and use of statins. The use of NSAIDs or 
statins was defined as at least two dispensed records within two years before the diagnosis of 
gastric adenocarcinoma. Four covariates were considered as potential effect modifiers and 
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were analysed with stratification, i.e., sex, age, tumour stage (Tis-II or III-IV), gastrectomy, 
and anatomical sub-locations of the gastric adenocarcinoma.  
Sensitivity analyses were conducted for the risk of disease-specific mortality to test the 
validity of the results, including a competing-risks model, exclusion patients with metformin 
monotherapy, and further adjusting for insulin use. We also analysed the influences of insulin 
or sulfonylureas on the risk of disease-specific mortality among metformin non-users to 
ensure the validity. The dosage of metformin use was also analysed in relation to the risk of 
disease-specific mortality among metformin users diagnosed after July 1st, 2007. Total DDD 
of metformin intake within two years before the diagnosis of gastric adenocarcinoma was 
categorized into quartiles and the median values of each category were tested for trend. The 
proportionality assumption for Cox regression was tested by the scaled Schoenfeld residuals 
and was met for all analyses. 
 
4.4 ETHICAL CONSIDERATIONS 
Study II is a systematic review and meta-analysis, thus an ethical approval is not needed. For 
the other studies in this thesis, ethical approvals were granted by relevant authorities before 
each study was conducted.  
The majority of the data in Study I were retrieved from the NSHDS, and an informed consent 
was obtained from each participant for each visit. Some data in Study I and all data in Study 
III-V came from Swedish national health data registries, where the data are collected during 
health care routines, and informed consents are exempted under the Swedish regulations. The 
linkage between registries was managed by the Swedish National Board of Health and 
Welfare and individual identifications were encrypted. The original data of the NSHDS were 
kept by the Umeå University and individual identifications were also encrypted. All data 
were stored on a safe server at Karolinska Institutet, and only a few members of the research 
group had the access to the data. All study results in this thesis were presented and published 







Main findings of the five studies are summarized in Figure 1.  
 
Figure 1. Main findings of Study I-V  
 
5.1 STUDY I 
Study I included 111,198 participants who were followed up for a median of 12.2 years. At 
inclusion, 5,958 (5.4%) participants had diabetes, 23,900 (21.5%) had prediabetes, and the 
remaining 81,340 (73.1%) were normoglycaemic. Table 1 presents the characteristics of 
participants by exposure groups at inclusion. Compared with the participants with normal 
blood glucose, prediabetes and diabetes participants were older, had more often BMI >27 
and a shorter period of education, but were healthier in terms of smoking habits. 
Table 1. Baseline characteristics of study participants 
Number (%) Normoglycaemic Prediabetes Diabetes 
 81,340 (73.1) 23,900 (21.5) 5,958 (5.4) 
Sex 
Male 40,481 (49.8) 11,023 (46.1) 3,363 (56.5) 
Age, years 
<40 20,462 (25.1) 3,221 (13.5) 473 (7.9) 
40 - 49 32,465 (39.9) 7,771 (32.5) 1,290 (21.7) 
50 - 59 20,577 (25.3) 8,517 (35.6) 2,408 (40.4) 
≥60 7,836 (9.6) 4,391 (18.4) 1,787 (28.1) 
Body mass index 
≤24 31,747 (39.0) 6,025 (25.2) 866 (14.5) 
24 - 27 25,233 (31.0) 6,857 (28.7) 1,212 (20.3) 
≥27 24,164 (29.7) 10,947 (45.8) 3,852 (64.7) 
Missing 196 (0.2) 71 (0.3) 28 (0.5) 
Education level 
Compulsory school or less 14,277 (17.5) 6,159 (25.8) 2,060 (34.6) 
Upper secondary school 41,298 (50.8) 11,575 (48.4) 2,729 (45.8) 
College or postgraduate 25,129 (30.9) 5,917 (24.8) 1,043 (17.5) 
Missing 636 (0.8) 249 (1.0) 126 (2.1) 
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Continued Table 1 
 Normoglycaemic Prediabetes Diabetes 
Smoking habits 
Never smoker 15,853 (19.5) 4,830 (20.2) 1,303 (21.9) 
Ex-smoker 23,027 (28.3) 7,440 (31.1) 2,036 (34.2) 
Current smoker 41,435 (50.9) 11,263 (47.1) 2,475 (41.5) 
Missing 1,025 (1.3) 367 (1.5) 144 (2.4) 
 
In total, 219 participants (0.2%) were diagnosed with gastric adenocarcinoma during the 
follow-up. The risk of gastric adenocarcinoma was not different between participants with 
diabetes or prediabetes and those without (Table 2). The adjusted risk of gastric 
adenocarcinoma was not increased with one unit increase of either fasting blood glucose 
(HR 1.02, 95% CI 0.91–1.14) or post-load glucose (HR 0.98, 95% CI 0.90–1.05).   
Table 2. Risk of gastric adenocarcinoma in participants exposed to prediabetes or diabetes compared with 
normoglycaemic participants. 
 Number of GAa Crude HR (95% CI)b Adjusted HRb (95% CI)c 
Normoglycemic  132 Reference Reference 
Prediabetes or diabetes 87 0.97 (0.74 - 1.28) 0.96 (0.73 - 1.27) 
Normoglycemic  135 Reference Reference 
Prediabetes  67 1.01 (0.81 - 1.45) 1.07 (0.79 - 1.44) 
Normoglycemic  132 Reference Reference 
Diabetes 17 0.83 (0.50 - 1.38) 0.77 (0.46 - 1.29) 
a GA: Gastric adenocarcinoma 
b Age was used as the time scale 
c Adjusted for sex, calendar year, BMI, tobacco smoking, and education level; age was used as the time scale 
 
5.2 STUDY II 
The systematic search identified 3,473 studies. After exclusions, 5 studies reporting serum 
HbA1c and 7 studies reporting serum glucose were included. Of these 12 studies, 11 were 
cohort studies and one was a nested case-control study. Most studies came from Asia (8/12) 
and were based on screening programmes or health surveys (9/12). Gastric cancer was 
presented as one of the multiple outcomes in half of the studies, while in the other half, 
gastric cancer was the primary outcome. The quality assessment with Newcastle-Ottawa 
Scale revealed that 7 studies had moderate to high risk of bias, while 5 studies had low risk of 
bias. 
Random-effects meta-analysis showed that elevated serum levels of HbA1c were associated 
with an increased risk of gastric cancer (pooled HR 1.36, 95% CI 1.06-1.74) and possibly 
also for serum glucose (pooled HR 1.11, 95% CI 0.98-1.26). There was moderate 
heterogeneity across studies reporting HbA1c (I2 = 43%, P in Q test = 0.43) and high 
heterogeneity across studies reporting serum glucose (I2 = 70%, P in Q test = 0.001). The 
subgroup analyses showed that adjustment for H. pylori infection may explain the 
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heterogeneity across studies reporting HbA1c, but not studies reporting serum glucose (Table 
3). 
Table 3. Subgroup meta-analyses for elevated serum levels of HbA1c and glucose in relation to risk 
of gastric cancer. 
 Serum HbA1c Serum glucose 
Study 
characteristics 
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W P value in the test of subgroup difference 
 
Asymmetry was detected in funnel plots both for studies reporting HbA1c and serum glucose, 
but only studies reporting serum glucose were shown by the Egger’s tests to be prone to 
publication bias (P for HbA1c = 0.292; P for serum glucose = 0.055). The pooled HR for 
serum glucose was slightly attenuated after imputing the potential missing study (pooled HR 
1.05, 95% CI 0.89-1.24). 
 
5.3 STUDY III 
Gastric adenocarcinoma was diagnosed in 23,591 individuals during the study period. 
Among them, around 12% had diabetes at diagnosis of gastric adenocarcinoma. 
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Gastrectomy was performed on 9,018 (38.2%) patients. The median follow-up for the total 
cohort was 0.59 years (interquartile range 0.18-1.75). Patients’ characteristics are presented 
in Table 4. Patients with diabetes were slightly older and had more comorbidities than those 
without diabetes. 






 20,785 (88.1) 2806 (11.9) 
Sex 
Male 12,752 (61) 1818 (65) 
Age 
<60 3273 (16) 279 (10) 
60 - 69 4339 (21) 575 (20) 
70 - 79 6997 (34) 1115 (40) 
≥80 6176 (30) 837 (30) 
Charlson Comorbidity Index score 
  0 13,645 (66) 1381 (49) 
  1 4937 (24) 824 (29) 
  ≥2 2203 (11) 601 (21) 
Tumour stage (from 2004) 
  I-II 1488 (33) 314 (36) 
  III-IV 2982 (67) 560 (64) 
Resectional surgery 
  No  12,793 (62) 1780 (63) 
  Yes 7992 (38) 1026 (37) 
 
Co-existing diabetes was associated with an increased risk of disease-specific mortality in 
the total cohort (adjusted HR 1.17, 95% CI 1.11-1.22) and the non-cardia sub-cohort 
(adjusted HR 1.17, 95% CI 1.10-1.23). The associations between diabetes and the increased 
risk of disease-specific mortality were pronounced among patients with no other 
comorbidities and who underwent gastrectomy (Table 5). The risk of all-cause mortality 
was increased in patients with diabetes compared with those without diabetes until 12 









Table 5.  Disease-specific mortality in patients with gastric adenocarcinoma (GA) with and without 




HR (95% CI) 
Multivariable modela 
HR (95% CI) 
Charlson Comorbidity Score  
0  
  No diabetes  8691 Reference Reference 
  Diabetes  691 1.21 (1.14-1.30) 1.23 (1.15-1.32) 
1  
  No diabetes  7633 Reference Reference 
  Diabetes  1086 0.92 (0.85-1.00) 0.95 (0.87-1.04) 
≥2  
  No diabetes  4461 Reference Reference 
  Diabetes  1029 0.95 (0.85-1.06) 1.01 (0.91-1.12) 
No gastrectomy  
  No diabetes  12793 Reference Reference 
  Diabetes  1780 1.00 (0.94-1.05) 1.04 (0.98-1.10) 
Gastrectomy  
  No diabetes  7992 Reference Reference 
  Diabetes  1026 1.24 (1.14-1.35) 1.27 (1.16-1.38) 
Tumour stagec  I-II 
  No diabetes  2982 Reference Reference 
  Diabetes  560  
  ≤6 months after diagnosis 1.29 (1.13-1.48) 1.26 (1.11-1.44) 
  >6 months after diagnosis 1.04 (0.88-1.22) 1.04 (0.88-1.22) 
Tumour stagec  III-IV 
  No diabetes  1488 Reference Reference 
  Diabetes  314  
  ≤6 months after diagnosis 1.35 (0.95–1.94) 1.32 (0.92–1.89) 
  >6 months after diagnosis 1.16 (0.93-1.44) 1.09 (0.88-1.36) 
a Adjusted for sex, age at cancer diagnosis, and calendar year of cancer diagnosis 






Figure 2.  Risk of all-cause mortality after gastrectomy for gastric adenocarcinoma comparing patients 
with and without diabetes. 
 
5.4 STUDY IV 
Study IV included 544,130 participants in the diabetes cohort and 4,525,543 participants in 
the matched cohort. At inclusion, 61.5% of the participants of the diabetes cohort and 9.1% of 
the matched cohort were metformin users. The baseline characteristics of participants 
included in each cohort are presented in Table 6.  
Table 6. Baseline characteristics of study participants in the diabetes cohort and the matched cohort. 









Total 334,506 (61.5) 209,624 (38.5) 411,413 (9.1) 4,114,130 (90.9) 
Sex  
Men 196,721 (58.8) 120,048 (57.3) 239,256 (58.2) 2,392,560 (58.2) 
Age at entry, mean ± 
standard deviation 
62.1 (±12.9) 61.4 (±19.5) 59.0 (±13.7) 59.0 (±13.7) 
Calendar year at entry 
2005 102,834 (30.7) 142,293 (67.9) 127,136 (30.9) 1,271,360 (30.9) 
2006-2010 111,199 (33.2) 41,432 (19.7) 146,175 (35.5) 1,461,750 (35.5) 
2011-2015 120,473 (36.0) 25,899 (12.4) 138,102 (33.6) 1,381,020 (33.6) 
Charlson comorbidity score* 
0 250,635 (74.9) 135,583 (64.7) 303,840 (73.9) 3,265,518 (79.4) 
1 59,847 (17.9) 43,510 (20.8) 75,396 (18.3) 618,631 (15.0) 
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Continued Table 6 









≥2 24,024 (7.2) 30,531 (14.6) 32,177 (7.8) 229,981 (5.6) 
Use of non-steroidal anti-inflammatory drugs or aspirin† 
No 175,589 (52.5) 109,565 (52.3) 247,988 (60.3) 3,048,169 (74.1) 
Yes 158,920 (47.5) 100,059 (47.7) 163,425 (39.7) 1,065,961 (25.9) 
Use of statin† 
No 162,671 (48.6) 129,555 (61.8) 22,841 (54.2) 3,377,102 (82.1) 
Yes 171,835 (51.4) 80,069 (38.2) 188,572 (45.8) 737,028 (17.9) 
* In the 10 years before study entry 
† In the year after study entry 
 
Participants were followed up for a median of 5.8 years, and 892 (0.1%) participants of the 
diabetes cohort and 6,395 (0.1%) of the matched cohort developed gastric adenocarcinoma 
during the follow-up. The risk of gastric adenocarcinoma and non-cardia adenocarcinoma 
was not decreased among metformin users compared with non-users in the diabetes cohort. 
The risk of gastric cardia adenocarcinoma was rather increased among metformin users 
compared with non-users in this cohort. In the matched cohort, metformin use was associated 
with an increased risk of developing gastric adenocarcinoma and its two subtypes (Figure 3). 
 
 
Figure 3. Risk of total, non-cardia and cardia gastric adenocarcinomas in metformin users compared with 




5.5 STUDY V 
Study V included 1,140 patients with diabetes and gastric adenocarcinoma. The majority 
(68.2%) of these patients were metformin users before the diagnosis of gastric 
adenocarcinoma. These metformin users were more often male, younger at cancer diagnosis, 
more likely to be treated with gastrectomy, and less likely to have comorbidities compared 
with non-users of metformin (Table 7).  
 
Pre-diagnosis use of metformin was associated with decreased risk of both disease-specific 
mortality (adjusted HR 0.79, 95% CI 0.67-0.93) and all-cause mortality (adjusted HR 0.78, 
95% CI 0.68-0.90) among patients with gastric adenocarcinoma. The results were not 
changed dramatically in the sensitivity analyses excluding patients with metformin 
monotherapy (adjusted HR 0.78, 95% CI 0.64-0.96) and further adjusting for insulin use 
(adjusted HR 0.82, 95% CI 0.69-0.97). The analyses of the other two anti-diabetes 
medications showed no association between the use of these medications and risk of disease-
specific mortality among metformin non-users (adjusted HR for insulin 1.14, 95% CI 0.86-
1.50; adjusted HR for sulfonylureas 1.07, 95% CI 0.80-1.43). The competing-risks model 
showed that metformin users had a decreased risk of mortality due to both gastric 
adenocarcinoma and other causes compared with non-users (Figure 4). Besides, the risk of 
disease-specific mortality was decreased among metformin users in subgroup analyses of 
female sex and advanced tumour stage (Table 8).  
Table 7. Characteristics of 1140 diabetes patients with gastric adenocarcinoma in Sweden in 2005-2018 
Number (%) Metformin users Metformin non-users 
Total 777 (68.2) 363 (31.8) 
Sex 
  Male 561 (72.2) 246 (67.8) 
Median age (interquartile range) 72 (65-78) 75 (68-82) 
Gastrectomy 
  Yes 221 (28.4) 76 (20.9) 
  No 556 (71.6) 287 (79.1) 
Charlson Comorbidity Index 
  0 495 (63.7) 172 (47.4) 
  1 184 (23.7) 96 (26.4) 




Figure 4. Cumulative disease-specific and other-cause mortality in patients with gastric adenocarcinoma 








Table 8. Risk of disease-specific mortality after gastric adenocarcinoma diagnosis in relation to 
metformin use among diabetes patients. 
 Disease-specific mortality 







    No metformin  155 Reference Reference 
    Metformin  312 0.75 (0.62-0.92) 0.85 (0.69-1.03) 
Women 
    No metformin  87 Reference Reference 
    Metformin  139 0.59 (0.45-0.77) 0.66 (0.49-0.89) 
Age <73 years 
    No metformin  80 Reference Reference 
    Metformin  218 0.78 (0.60-1.00) 0.83 (0.64-1.09) 
Age ≥73 years 
    No metformin  162 Reference Reference 
    Metformin  233 0.71 (0.58-0.87) 0.80 (0.64-0.99) 
Gastric cardia adenocarcinoma 
    No metformin  58 Reference Reference 
    Metformin  127 0.70 (0.51-0.96) 0.82 (0.60-1.14) 
Gastric non-cardia adenocarcinoma 
    No metformin  185 Reference Reference 
    Metformin  324 0.71 (0.59-0.85) 0.79 (0.65-0.95) 
Tumour stage Tis-II 
    No metformin  37 Reference Reference 
    Metformin  78 0.73 (0.49-1.08) 0.87 (0.57-1.31) 
Tumour stage III-IV 
    No metformin  141 Reference Reference 
    Metformin  303 0.66 (0.54-0.80) 0.71 (0.58-0.88) 
No gastrectomy 
    No metformin  202 Reference Reference 
    Metformin  347 0.71 (0.60-0.84) 0.82 (0.68-0.99) 
Gastrectomy‡ 
    No metformin  40 Reference Reference 
    Metformin  104 0.81 (0.56-1.16) 0.87 (0.60-1.27) 
† Adjusted for sex, age, calendar year of gastric adenocarcinoma diagnosis, use of non-steroidal anti-
inflammatory drugs or aspirin, use of statins, and Charlson Comorbidity Index. 




6.1 METHODOLOGICAL CONSIDERATIONS 
6.1.1 Design 
In this thesis, Study I, III-V were cohort studies and Study II was a systematic review and 
meta-analysis. The methodological considerations are different for these two study designs. 
6.1.1.1 Cohort study 
A cohort study, by definition, is to identify a group of people from a study population and 
follow them over a certain period. These people in the cohort are classified as ‘exposed’ or 
‘unexposed’. At the end of follow-up, the occurrence of the outcomes is compared between 
the exposed and unexposed groups. The cohort study is a type of observational study and is 
levelled third in the hierarchy of scientific evidence, following systematic review and meta-
analysis of randomized controlled trials (RCTs) and individual RCTs. Although RCTs are 
regarded superior to cohort studies, they are not always feasible due to limited resources or 
ethical considerations, under which conditions the cohort study is sometimes a solution 
balancing validity and feasibility. If well conducted, cohort studies could provide evidence to 
suggest (but may not prove) causation. The current thesis aimed to investigate diabetes or use 
of metformin in relation to the risk and prognosis of gastric adenocarcinoma. The exposures 
are either not possible to randomize (diabetes) or at a too early stage to launch an RCT due to 
limited evidence (metformin use). Therefore, cohort studies may be the optimal study design 
for these topics at the current stage. 
6.1.1.2 Systematic review and meta-analysis 
The systematic review and the meta-analysis are approaches to summarize all relevant 
evidence for a pre-defined research question. To achieve this aim, a systematic search is 
performed to find as much evidence as possible. The quality of the evidence is evaluated 
during the systematic review process, and the results are synthesized with statistical methods 
during the meta-analysis process. An important consideration of meta-analysis is the 
homogeneity of included studies, which not only supports the rationale to synthesize results 
but also guides the choice of fixed-effect or random-effects models.109 Several systematic 
reviews and meta-analyses have been done to assess the association between diabetes and 
risk of gastric cancer.60, 110, 111 These meta-analyses have shown high heterogeneity (I2 
ranging from 70% -95%) across the included studies, likely caused by different definitions of 
diabetes in individual studies, undermining the interpretation of the results. Thus, the 
motivation to conduct a systematic review and meta-analysis with homogenous studies 
shaped the choice of diabetes biomarkers as the exposure of interest for Study II.   
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6.1.2 Internal validity 
6.1.2.1 Selection bias 
Selection bias arises from the inclusion of study participants conditioning on a factor that is 
the common effect of the exposure and the outcome.112 Informative censoring, volunteer bias, 
healthy worker bias, and pre-treatment bias are different kinds of selection biases. Because 
the outcomes of Study I, III-V were all identified from national registries and were virtually 
complete, informative censoring should not be a problem in these studies. In Study I, 
participants were included only if they agreed to participate and provided self-reported 
diabetes status or blood samples for OGTT. This volunteer-based design was potentially 
vulnerable to selection bias. The overall participation rates of VIP and MONICA were around 
50%-60%, and 0.5% of the participants had no information on either self-reported diabetes 
status or OGTT results.104, 105 However, the cancer incidence among participants of the VIP 
and MONICA is comparable to that of the background population, reducing the possibility of 
selection bias in this study.113 In the two studies (IV and V) of which the exposure was 
metformin use, pre-treatment bias was possible because the studies included both new and 
prevalent users of metformin. The two problems related to the inclusion of prevalent users 
were 1) the inability to identify events that occur shortly after initiation of the therapy and 2) 
the inability to control for disease risk factors that might be altered by the study drugs used 
before the cohort entry.114 Only the first one is a type of selection bias and such bias was not 
likely to exist in these two studies given the following reasons. For Study IV, the outcome 
was gastric carcinogenesis of which the process generally lasted for years, and thus unlikely 
to be an early event. For Study V, the outcome was mortality after diagnosis of gastric 
adenocarcinoma, and metformin users and non-users were uniformly included at their 
diagnosis of gastric adenocarcinoma, precluding any missing events.  
6.1.2.2 Information bias 
Information bias occurs if the information is not accurately collected from study participants. 
For categorical variables, information bias is also called misclassification. Information bias 
could happen for every variable within a study, but is most of a concern when the exposure or 
the outcome is misclassified. Misclassification can be nondifferential or differential. 
Nondifferential misclassification refers to the misclassification that is not related to other 
variables, e.g., nondifferential misclassification of the exposure is not related to the outcome. 
Differential misclassification means that it differs according to another variable. In study I, 
the exposure was identified by either self-report diabetes or an OGTT whose results showed 
increased glucose levels, while the unexposed participants were identified by both self-
reported non-diabetes and a normal result of the OGTT. These definitions reduced the risk 
that participants were misclassified between the exposed and unexposed groups. In study III, 
the exposure was diabetes diagnosis as retrieved from the Patient Registry, where diagnoses 
from primary care centers were lacking. However, such misclassification should be limited 
because most included patients should have been hospitalized or seen at a specialist out-
patient care for gastric adenocarcinoma and their diagnosis of diabetes should be thus 
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included in the Patient Registry. In Study IV and V, metformin is a prescription-only 
medication in Sweden and metformin use was based on dispensed records identified from the 
Prescribed Drug Registry, which should be accurate and complete. However, the dispensed 
records of metformin were not equal to the amounts of metformin actually taken by the 
patients. Hence, there is still some possible misclassification of the metformin use. 
Nevertheless, such misclassification is likely to be non-differential since it is not related to the 
outcome, i.e. occurrence of gastric adenocarcinoma or death due to gastric adenocarcinoma, 
and thus might only dilute the associations, but not explain them. For all cohort studies 
included in this thesis, the outcomes were retrieved from the Cancer Registry or the Cause of 
Death Registry. The accuracy of data in these two registries has been well validated (more 
details available in the ‘Data sources’ section), therefore the probability of misclassification 
of the outcomes is low. 
6.1.2.3 Confounding 
Confounding, in a simple definition, is the confusion of effects.115 Confounding occurs when 
the effect of the exposure on the outcome is mixed with the effect of other variables 
(confounders). Thus, a confounder is the common cause (or the proxy of the common cause) 
of the exposure and the outcome and should not be a descendant of the exposure.116 
Confounding is the key bias that differentiates RCTs and observational studies. If the 
randomization process is well-performed and the trial is large enough, the RCTs are in theory 
exempt from confounding issues. While in observational studies, confounding only 
disappears when all the confounders are measured and properly dealt with, which is generally 
not guaranteed in practice.  
In the four cohort studies of this thesis, confounding was considered with maximum 
utilization of the available data. In Study I, several variables were considered as potential 
confounders and the final selection of the six potential confounders was based on both 
available knowledge and the backward statistical selection. Although the selection of 
confounders by the statistical model is generally not recommended,117 a trade-off has to be 
made between sufficient adjustment for confounders and preservation of statistical power. 
Among potential confounders that were not adjusted for in this study were H. pylori infection 
and the use of medications, e.g. statins and metformin, which were not available in the 
dataset. However, whether H. pylori infection is associated with diabetes is not well-
established and the majority of the exposed patients were exposed to prediabetes for whom 
drug treatments are usually not needed. 
In Study IV, the data on H. pylori infection was also lacking, but H. pylori eradication 
treatment was adjusted for as a surrogate for H. pylori infection. The results of the matched 
cohort in this study were believed to be influenced by confounding by diabetes, thus the 
results of the diabetes cohort were more valid. The increased risk of gastric cardia 
adenocarcinoma among metformin users in this study may be explained by unmeasured 
confounding by obesity, which is one of the major weaknesses of this study. With the method 
proposed by Tyler et al.,118 an unmeasured confounder that was associated with both the 
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metformin use and gastric cardia adenocarcinoma by a relative risk of 2.3 was sufficient to 
explain the increased risk, and adjustment for an unmeasured confounder by a relative risk of 
1.4 could lead to the adjusted 95% CI to include 1. According to the literature, diabetes 
patients taking metformin were two times more likely to be obese compared with other 
diabetes patients,94 and the relative risk of obesity in relation to the risk of gastric cardia 
cancer varies between 1.4-3.0.119 This indirect evidence supports a role of confounding by 
obesity in this study. 
In Study III and V, lifestyle factors such as smoking or physical activity might also act as 
potential confounders, but were not available in the dataset. However, the influence of these 
factors on the prognosis of gastric adenocarcinoma should be limited compared with that of 
the tumour stage or gastrectomy, and should thus not introduce substantial confounding bias 
even if not adjusted for. Besides, based on the knowledge acquired in Study III that diabetes 
worsened the prognosis of gastric adenocarcinoma, the study patients of Study V were 
restricted to diabetes patients, which counteracted the confounding by diabetes in this study.  
Despite the above-mentioned efforts, unmeasured or residual confounding always exists in 
observational research, including each of the cohort studies in this thesis. 
6.1.2.4 Bias related to pharmacoepidemiology studies 
Immortal time bias is common in pharmacoepidemiology studies and may influence the 
validity of the study results.32 Immortal time bias arises when the unexposed time is 
mistakenly classified as the exposed time (or vice versa), and could thus distort the 
associations.120 In Study IV, this bias was avoided by the inclusion of participants at their first 
dispensation date of anti-diabetes medications in the diabetes cohort and matching on the 
same entry day in the matched cohort. Additionally, the exposure status was allowed to 
change in this study. In Study V, this bias was not a problem because participants were 
included uniformly at their diagnosis date of gastric adenocarcinoma.  
Another common bias inherent in pharmacoepidemiological studies is confounding by 
indication, i.e. the indication for the treatment also affects the occurrence of the outcome. 
Thus, the observed association between the treatment and the outcome could partly be 
attributed to the indication for which the treatment is prescribed. Confounding by disease 
severity is a subtype of confounding by indication121 and is possible in Study IV and V since 
the comparison is made between metformin, a first-line treatment for diabetes, and other anti-
diabetes treatments. The adjustment for use of statins might partly counteract this bias. Since 
statin is used for the prevention or treatment of macrovascular diseases, which are common 
morbidities of diabetes, the use of statin could reflect diabetes severity to some extent.122 
Besides, the null association found in Study IV was not likely to be explained by this bias 
because such bias would distort the associations towards the opposite direction. In Study V, 
this bias was addressed in the sensitivity analysis that further adjusted for insulin use and the 
risk estimate was not changed. 
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A third common problem was bias due to time lag and latency which may occur when the 
effect of a first-line treatment is compared with second- or third- line treatments.32 It is 
possible that due to the long latency of the outcome, the effect of the first-line treatment on 
the outcome is observed during the exposure period of the second-line treatment. Such bias is 
plausible for metformin studies because almost all drug treatments for type 2 diabetes start 
from metformin. In Study IV, the influence of this potential bias was partly removed in the 
sensitivity analysis excluding gastric adenocarcinoma occurred within the first year of follow-
up. While in Study V, a two-year exposure window was used and the exposure status was not 
allowed to change after the inclusion, decreasing the possibility of this bias. 
6.1.2.5 Bias in the systematic review and meta-analysis 
A systematic review and meta-analysis of RCTs is usually acknowledged as the highest level 
of scientific evidence, but doubts have been posed on which evidence level a systematic 
review and meta-analysis of observational studies should locate. The major concerns are the 
lower internal validity of observational studies compared with RCTs, and the difficulty to 
assess the risk of bias both within and across studies.123 In the systematic review and meta-
analysis of this thesis, combined efforts were made to minimize this problem, including 
following a pre-defined protocol, critically assessing the quality of the included studies, and 
reporting the results according to the guidelines.124, 125 
Another concern on systematic review and meta-analysis is potential publication bias, mainly 
caused by the differential publication of studies reporting relatively large effects or including 
large sample sizes.126 In other words, small studies with null or weak effects are less reported 
and might thus not be included in the meta-analysis. A preliminary method to assess 
publication bias is through checking the asymmetry of funnel plots (Figure 5). The funnel 
plots of serum glucose showed that a small study reporting a strong association was included, 
while on the opposite side, small studies might be missing. On the other hand, the funnel 
plots of HbA1c showed inclusion of a small study reporting null association, while small 
studies reporting strong associations might be missing. Therefore, although asymmetry was 
identified in both plots, studies reporting serum glucose were more prone to publication bias, 
which was also shown by the results of the Egger’s test. As expected, the pooled association 
between serum glucose levels and risk of gastric cancer weakened after trim-and-fill 




Figure 5. Funnel plots for studies reporting serum glucose and HbA1c. 
6.1.3 Random error  
While different biases are regarded as systematic errors that influence the internal validity of 
study results, random error is regarded another problem that alters the precision of study 
results. Random errors are inevitable and unpredictable, but could be reduced by increasing 
the sample sizes. In this thesis, Study III-V were based on nationwide cohorts, which helped 
to decrease random errors. The meta-analysis in Study II was another way to increase sample 
sizes by combining results from several studies. However, when conducting subgroup 
analysis, the sample size is usually divided into several parts and the risk of random error 
increases.  
Two types of errors may occur in the statistical assessments, i.e., type I error (false positive) 
and type II error (false negative). Type I error occurs when a true null hypothesis is rejected. 
Under the null hypothesis, an event has a certain probability called P-value of the 
significance of the test. The P-value is usually compared to a predetermined cut-off called the 
level of the test, which is empirically set at 5% for a single test. If the P-value is lower than 
that level, the null hypothesis is rejected. Although the P-value has a long history, the use has 
been discouraged by many scientists.127-129 Alternatively, 95% CIs can be used. The 95% CI 
is an interval estimation and could be interpreted as to be 95% confident that the true value of 
the population is included within this interval. The 95% CIs were used throughout the studies 
in this thesis as they informed not only statistical significance, but also the precision and 
direction of the associations.130 A common source of type I errors is multiple testing. In this 
thesis, we reduced the number of tests by strictly following detailed and pre-defined study 
protocols for all studies. Type II error, on the other hand, occurs when the null hypothesis is 
not rejected but a true alternative value exists. The complement to the probability of type II 
error is called power, and the power can be increased by enlarging the sample size, improving 
the efficiency of statistical methods, reducing the variability in the sample, or looking for 
larger differences between the null and the alternative hypotheses. From a post hoc point of 
view, Study I might be underpowered for the reason that it was based on countywide cohorts 
and the incidence of the outcome (gastric adenocarcinoma) was rare. Another explanation 
might be that the true difference between the exposed and unexposed was small that could 
not be detected under this sample size. 
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6.1.4 External validity 
The external validity, or generalizability, of a study is the possibility to extrapolate the results 
to another population. This is often an advantage of cohort studies over RCTs because the 
results of cohort studies may be easily applied to real-world settings, while the results of 
RCTs are usually based on highly selected and homogenous populations. However, internal 
validity is the precondition of external validity and always overweighs the value of external 
validity. In general, the results of Study III and V are less likely to be severely influenced by 
different errors and thus are credited with higher external validity. However, given that the 
results of Study III and V were based on a single population and that the sample sizes were 
not large enough for robust stratification analyses, the results might only be generalized to 
populations that are similar to the Swedish population. 
 
6.2 GENERAL DISCUSSION 
6.2.1 Strengths and weaknesses 
Shared strengths of Study I, and III-V are the population-based cohort design, complete 
follow-up, and adjustment for several potential confounders. Moreover, whenever possible, 
gastric non-cardia and cardia adenocarcinomas were analysed separately. A major weakness 
of these studies was the lack of information on some potential confounders as discussed 
above. Besides, the information on some potential effect modifiers, e.g. neoadjuvant therapy 
in Study III and V, was also not available. The strength of the systematic review and meta-
analysis includes the well-defined research question, quality assessment of included studies, 
as well as assessment of publications bias. Furthermore, Study II might be the first study 
quantitively synthesized the association between objectively measured serum levels of 
HbA1c or glucose and the risk of gastric cancer. Yet, the weakness of this study was the 
limited number of studies and the unexplained heterogeneity across studies reporting serum 
glucose. 
 
6.2.2 Study I, II and IV 
The results of Study I showed that prediabetes or diabetes did not increase the risk of 
developing gastric adenocarcinoma. On the other hand, the results of Study II (a systematic 
review and meta-analysis) showed that serum HbA1c, and presumably serum glucose also, 
were associated with an increased risk of gastric cancer. In general, the evidence grade of a 
systematic review and meta-analysis is considered higher than that of a single cohort study. 
The explanations for the seemly contradictory results between Study I and II might be the 
lack of statistical power in Study I (type II error) or differences in study designs and study 
populations (Study I: Swedish population, and Study II: multiple populations of which most 
were from East Asia). Another factor that may contribute to the results of Study I was that the 
VIP, where the majority of the participants came from, was originally designed as an 
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individual-tailored health promotion program aiming to reduce the morbidity and mortality 
from cardiovascular disease and diabetes. The evaluation of this program showed that it 
reduced all-cause and cardiovascular mortality among the participants.131 Thus, factors 
associated with both cardiovascular death and gastric adenocarcinoma (e.g. smoking habits) 
might have been changed due to the intervention during the follow-up. Although the exposure 
status of diabetes or prediabetes was allowed to change in Study I, the confounders were 
adjusted only by their baseline values. Therefore, it is possible that some time-varying 
factors, measured or unmeasured, were not fully accounted for in this study.  
Dependence on exposure duration might partly explain why in Study II, serum HbA1c levels 
were associated with an increased risk of gastric cancer, but the association was less evident 
for serum glucose levels. This finding was also supported by another study showing that only 
the trajectory pattern of elevated serum glucose that lasted for a long period was associated 
with an increased risk of gastrointestinal cancer.132 Previous systematic reviews and meta-
analyses that investigated diabetes in relation to the risk of gastric cancer showed inconsistent 
results and there was high heterogeneity across the included studies.60, 110, 111, 133, 134 The 
inclusion of only studies reporting serum biomarkers reduced the heterogeneity in the 
analysis of HbA1c. Why high heterogeneity remained in the analysis of serum glucose could 
be attributed to the different categorizations of glucose levels in the included studies, and the 
synthesis of results of both fasting and non-fasting serum glucose. An optimal solution would 
be analysing fasting and non-fasting serum glucose separately and only combining studies 
with similar categorizations, but this was not possible because of the limited number of 
studies. An interesting finding in the meta-analysis of studies reporting HbA1c was the 
different pooled estimates in studies that adjusted for H. pylori infection and those that did 
not. H. pylori infection is a known risk factor for gastric cancer, but its association with 
diabetes or hyperglycaemia is not well understood. Therefore, whether H. pylori infection is a 
confounder or effect modifier in the associations between hyperglycaemia and gastric cancer 
should be explored in future studies. 
The results of Study IV showed that use of metformin did not decrease the risk of gastric 
adenocarcinoma, which was consistent with some previous studies,93, 135 but not others.91, 92 A 
recent systematic review and meta-analysis showed decreased risk of gastric cancer 
associated with metformin use only among Asian populations, but not Western populations.96 
Thus, population differences might partly explain the different results between Study IV and 
some other studies. When designing Study IV, the construction of the matched cohort was 
based on the knowledge obtained from previous Study I, i.e. that diabetes might not influence 
the risk of gastric adenocarcinoma. However, the distinct results found in the matched cohort 
and diabetes cohort suggest an association between diabetes and the development of gastric 
adenocarcinoma, further supporting the findings of the systematic review and meta-analysis 
(Study II). In other words, diabetes was likely a confounder or closely correlated with a 
confounder in the association between metformin use and risk of gastric adenocarcinoma. 
Hence, the results of the diabetes cohort were probably less prone to confounding bias. The 
still significant association between metformin use and increased risk of gastric cardia 
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adenocarcinoma after restriction to diabetes patients could be potentially explained by 
confounding by obesity as discussed above.  
 
6.2.3 Study III and V 
Both Study III and V were based on patients diagnosed with gastric adenocarcinoma in 
Sweden. The exposures were co-existing diabetes (Study III) and metformin use (Study V) 
before the diagnosis of gastric adenocarcinoma. The primary outcome was disease-specific 
mortality in both studies. The results of Study III showed co-existing diabetes was associated 
with a worse prognosis in gastric adenocarcinoma, and this association was most pronounced 
in patients who underwent gastrectomy. This might be due to that patients who underwent 
gastrectomy had a longer period of survival than those who did not, which allowed the 
influence of co-existing diabetes to be observed. Hyperglycaemia might play a role in the 
associations between diabetes and increased risk of mortality in gastric adenocarcinoma. 
Diabetes patients are more vulnerable to glucose turbulence than non-diabetes individuals 
under certain stress such as gastrectomy, and poor glycaemic control is associated with an 
increased risk of postoperative mortality.136-138   
Based on the results in Study III that diabetes increased the risk of mortality in gastric 
adenocarcinoma, Study V was designed among diabetes patients only to avoid confounding 
by diabetes. The results of Study V showed pre-diagnosis use of metformin was associated 
with better survival in gastric adenocarcinoma. This finding was supported by four previous 
studies,139-142 while the results from two other studies were not consistent.143, 144 The number 
of patients included in Study V was more than any of these six studies. Different mechanisms 
may explain the protective role of metformin in the prognosis of gastric adenocarcinoma, 
including a direct influence on the tumour-related pathways,145 an indirect influence on 
balancing glucose and insulin levels,31 and a synergistic influence with chemotherapy.146 
However, the glycaemic control among metformin users should not be better than that of 
patients using other anti-diabetes medications,139 suggesting that the glucose-lowering 
function may not be the main mechanism of metformin to decrease the mortality. The 
associations between metformin use and decreased mortality in gastric adenocarcinoma was 
pronounced among patients with more advanced tumour stage. Since patients with advanced 
tumour stage are usually treated with chemotherapy, the associations found in this subgroup 






• Elevated serum levels of HbA1c might increase the risk of gastric cancer. 
• Diabetes may increase the risk of disease-specific mortality among patients diagnosed 
with gastric adenocarcinoma. 
• Metformin use may not prevent gastric adenocarcinoma among diabetes patients. 
• Pre-diagnosis use of metformin may reduce the risk of mortality in gastric 





8 FUTURE PERSPECTIVES 
The associations between diabetes or its biomarkers and the risk of gastric adenocarcinoma 
should be further investigated in future studies, especially in western populations. The role 
of other factors, e.g. sex, ethnicity, or known risk factors of gastric cancer, in the 
association between diabetes and gastric carcinogenesis is not clear and large population-
based studies are needed. Although the existing evidence may suggest that individuals with 
poor glycaemic control have a higher risk of developing gastric adenocarcinoma compared 
with those of normoglycaemia, whether they can benefit from stricter glycaemic control is 
not known. For RCTs of which diabetes medications are the intervention and intermediate 
glucose metabolism is measured, secondary analyses for gastric adenocarcinoma incidence 
may help to elucidate this question, given the follow-up is long enough and the sample size 
is adequately large.  
Diabetes might worsen the prognosis in gastric adenocarcinoma after gastrectomy, but 
whether intensive perioperative glucose management could improve the survival in gastric 
adenocarcinoma is not clear. RCTs have found that intensive glucose control decreases 
morbidity, but not mortality among surgical patients with diabetes.147, 148 Since intensive 
glycaemic control may increase the risk of lethal hypoglycaemia, careful serum glucose 
management during the perioperative period among patients with gastric adenocarcinoma is 
needed and both benefits and risks should be taken into account.  
Future studies aiming to analyse the role of metformin use in the development of gastric 
adenocarcinoma should restrict the study population to diabetes patients and separately 
analyse gastric cardia and non-cardia adenocarcinoma. Moreover, confounding by obesity 
should be considered during the study design. 
Although metformin use may be associated with improved survival among diabetes patients 
with gastric adenocarcinoma, whether this association is possible to extrapolate to non-
diabetic individuals is not known and well-designed cohort studies are needed. Future 
studies should also explore if the association varies for different doses, duration, and timing 
of metformin use. Currently, the evidence is far from enough to support an RCT of 
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Supplementary Table 1. Codes for identifying covariates in different Swedish health data registries. 
Covariate Version Codes 
The Swedish Cancer Registry 
  Adenocarcinoma WHO/HS/CANC/24.1 096, 196 
  Any cancer (excluding non-melanoma skin cancer) ICD-7 140-209, excluding 191 
  Gastric cancer ICD-7 151 
  Gastric cardia cancer ICD-7 151.1 
The Swedish Patient Registry 
   Diabetes ICD-9-SE 250 
   Diabetes ICD-10-SE E10-E14 
   Gestational diabetes ICD-10-SE O24.4 and O24.9 
   Gastrectomy before 1997 4411-4420, 4422, 4424-
4426, 4429, 4430, 4432, 
4434, and 4435 
   Gastrectomy After 1997 JDC and JDD 
   Polycystic ovary syndrome ICD-9-SE 256E 
   Polycystic ovary syndrome ICD-10-SE E28.2 
The Swedish Cause of Death Registry 
   Gastric cancer ICD-9 151 
   Gastric cancer ICD-10 C16 
   Oesophageal cancer ICD-10 C15 
The Swedish Prescribed Drugs Registry 
   H. pylori eradication package ATC A02BD 
   Insulin and analogues ATC A10A 
   Metformin ATC A10BA02 
   Metformin included in the combined medication ATC A10BD02 A10BD03 
A10BD05 A10BD07 






   Non-steroidal anti-inflammatory drugs ATC M01A, N02BA, 
B01AC06 





   Oral glucose lowering drugs   ATC A10B 
   Statins ATC C10AA, C10B 
   Sulfonylureas ATC A10BB 
